J. Montaner

发表

Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience.

B. Gazzard, B. Larder, J. Metcalf, 2011, AIDS patient care and STDs.

Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios

J. Montaner, A. Hill, E. Acosta, 2001, The Lancet.

Canadian Multicenter Azidothymidine Trial: AZT Pharmacokinetics

J. Ruedy, J. Montaner, C. Tsoukas, 1991, Journal of acquired immune deficiency syndromes.

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA

B. Gazzard, J. Montaner, S. Staszewski, 2001, AIDS.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

S. Hammer, J. Montaner, D. Cooper, 2001, JAMA.

Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance.

J. Arenillas, F. Purroy, J. Masjuán, 2021, Neurologia.

Prediction of clinical benefits of ritonavir‐boosted TMC114 from treatment effects on CD4 counts and HIV RNA

A. Hill, J. Montaner, C. Smith, 2007, HIV medicine.

Proteomic discovery and verification of serum amyloid A as a predictor marker of patients at risk of post-stroke infection: a pilot study

Jean-Charles Sanchez, J. Montaner, M. Katan, 2017, Clinical Proteomics.

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

B. Gazzard, R. Kaiser, B. Larder, 2021, The Journal of antimicrobial chemotherapy.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings

Dechao Wang, Shanmugam Saravanan, John Baxter, 2018, The Journal of antimicrobial chemotherapy.

Didanosine Compared with Continued Zidovudine Therapy for HIV-Infected Patients with 200 to 500 CD4 Cells/mm3: A Double-Blind, Randomized, Controlled Trial

M. Wainberg, M. Schechter, H. Salomón, 1995, Annals of Internal Medicine.

Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa

B. Larder, P. Reiss, S. Emery, 2016, Southern African journal of HIV medicine.

Antiretroviral Treatment (ART) of Adult HIV Infection

J. Montaner, P. Cahn, J. Aberg, 2010 .

Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.

J. Montaner, M. Dohn, R. A. McIvor, 1999, The Journal of infectious diseases.

UvA-DARE ( Digital Academic Repository ) Clinical implications of immune recovery during antiretroviral treatment for HIV infection

A. Ghani, J. Gatell, J. Montaner, 2012 .